Charles E. Alpers

About

Charles E. Alpers, M.D., is a Professor in the Department of Laboratory Medicine and Pathology at the University of Washington. He is the Director of the Alpers Lab, which is part of the Laboratory of Renal Pathology within the Department of Laboratory Medicine & Pathology at UW Medicine. His role involves leading research efforts in renal pathology, contributing to the understanding of kidney diseases through laboratory and clinical research. The lab focuses on pathology research services, and Dr. Alpers's work supports the department's mission in advancing diagnostic and research capabilities in renal pathology.

Research topics

• Medicine
• Internal medicine
• Endocrinology
• Biology
• Bioinformatics
• Pharmacology
• Computational biology
• Gastroenterology
• Evolutionary biology
• Genetics

Selected publications

• An atlas of healthy and injured cell states and niches in the human kidney

  Nature · 2023 · 631 citations

  . Here we applied multiple single-cell and single-nucleus assays (>400,000 nuclei or cells) and spatial imaging technologies to a broad spectrum of healthy reference kidneys (45 donors) and diseased kidneys (48 patients). This has provided a high-resolution cellular atlas of 51 main cell types, which include rare and previously undescribed cell populations. The multi-omic approach provides detailed transcriptomic profiles, regulatory factors and spatial localizations spanning the entire kidney.…

  PublisherOA PDFDOI

• Molecular mechanisms and therapeutic targets for diabetic kidney disease

  Kidney International · 2022 · 597 citations

  DOI

• Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

  The Lancet · 2023 · 254 citations

  BACKGROUND: Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT trial's previously reported interim analysis. Here, we report kidney function and outcomes over 110 weeks from the double-blind final analysis. METHODS: PROTECT, a double-blind, randomised,…

  PublisherOA PDFDOI

• Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

  The Lancet · 2023 · 212 citations

  PublisherOA PDFDOI

• Multicenter Clinicopathologic Correlation of Kidney Biopsies Performed in COVID-19 Patients Presenting With Acute Kidney Injury or Proteinuria

  American Journal of Kidney Diseases · 2020 · 186 citations

  PublisherOA PDFDOI

Recent grants

• NIH Grant R01DK083391

  NIH · $1.7M · 2016

• NIH Grant R01DK040802

  NIH · $364k · 1992

• NIH Grant P50HL047151

  NIH · $2.8M · 1997

Frequent coauthors

• Kelly L. Hudkins

  Northwestern University

  242 shared

• Agnes B. Fogo

  182 shared

• Behzad Najafian

  University of Washington

  100 shared

• Frank Eitner

  90 shared

• Stuart J. Shankland

  88 shared

• Mark A. Lusco

  University of Rochester Medical Center

  84 shared

• Richard J. Johnson

  University of Colorado Anschutz Medical Campus

  78 shared

• Stephan Segerer

  Kantonsspital Aarau

  75 shared

Labs

• Alpers LabPI

Education

• M.D.

  University of Washington

• M.S.

  University of Washington

• B.S.

  University of Washington

Awards & honors

• Elected Fellow of the American Association for the Advanceme…

Similar researchers at University of Washington

• William Altemeierh-66
• Cynthia A. Derdeynh-55
• Geoffrey S. Bairdh-35